Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech public health

Gavi Forecasts New TB Vaccines Saving 7.3M Lives

Analysis based on 19 articles · First reported Sep 14, 2026 · Last updated Sep 14, 2026

Sentiment
15
Attention
2
Articles
19
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The announcement is positive for vaccine manufacturers and global health financiers, signaling a large future market of roughly 85 million courses annually and potential regulatory approvals by 2029. However, the impact is long-dated and contingent on financing and manufacturing capacity, so near-term equity moves in pharma are likely limited.

pharmaceuticals vaccines global health

GAVI announced on Monday that new tuberculosis vaccines expected to become available from 2029 could save up to 7.3 million lives between 2030 and 2050, and unlock up to $135 billion in economic benefits across low- and middle-income countries. Gavi CEO Sania Nishtar called the pipeline candidates the next blockbuster immunisation tool, but warned that governments and manufacturers must prepare now to ensure sufficient, predictable and affordable supply for high-burden countries. Tuberculosis remains the world's leading infectious killer, with an estimated 10.7 million people developing the disease and 1.2 million dying in 2024, according to the World Health Organization. The only currently licensed vaccine, Bacille Calmette-Guerin, is over 100 years old and its protection wanes, leaving adolescents and adults unprotected. Gavi said demand among low- and middle-income countries could average 85 million vaccination courses annually, with higher demand in early years. The estimates are based on preliminary modelling by the London School of Hygiene and Tropical Medicine, assuming 50 percent efficacy and waning immunity over 10 years. Gavi identified risks including inadequate financing, demand uncertainty, limited manufacturer capacity and evidence gaps. It said it is working with partners, including through the WHO TB Vaccine Accelerator's Finance and Access Working Group, to lay groundwork for timely access. Separately, the Serum Institute of India signed a deal with the Gates Foundation to manufacture a novel TB vaccine candidate, and the India — Indian Council of Medical Research reported that India contributes about one-fourth of the world's TB burden.

55 GAVI released analysis
35 World Health Organization reported TB statistics
ngo
Gavi is the central actor, releasing the analysis and coordinating supply and access efforts for future TB vaccines. The announcement reinforces its role as the key global vaccine procurement and financing alliance.
Importance 100.0 Sentiment 20.0
per
As Gavi CEO, Nishtar is the public face of the announcement, framing the vaccines as a potential blockbuster tool and urging supply preparedness. Her statements drive the event's messaging.
Importance 70.0 Sentiment 10.0
priv
Serum Institute signed a deal with the Gates Foundation to manufacture a novel TB vaccine candidate, positioning it as a key future supplier. The deal could expand its vaccine portfolio and revenue if candidates succeed.
Importance 45.0 Sentiment 15.0
ngo
WHO provides the baseline TB mortality statistics cited and co-hosts the TB Vaccine Accelerator working group that Gavi partners with. Its data underpins the case for new vaccines.
Importance 40.0 Sentiment 5.0
ngo
The Gates Foundation signed a manufacturing deal with Serum Institute, continuing its role as a major funder of global health vaccine development. The partnership supports the pipeline Gavi hopes to deploy.
Importance 40.0 Sentiment 10.0
cnt
India bears roughly a quarter of global TB cases and hosts vaccine trials, making it a critical market and manufacturing base for future TB vaccines. Successful rollout would reduce disease burden and could lower long-term healthcare costs.
Importance 30.0 Sentiment 0.0
govactor
ICMR reported that India accounts for about one-fourth of the world's TB burden, highlighting the scale of need in a key country. Its data supports the demand case for new vaccines.
Importance 25.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.